Eli Lilly And Co vs VanEck Semiconductor ETF — how do they compare? Eli Lilly And Co trades at $1,159.69 (market cap $1.02T), while VanEck Semiconductor ETF trades at $584.24. The key difference: Eli Lilly And Co pays a 0.6% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals.
| LLY | SMH | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $668.91 |
52-Week Low | $625.65 | $283.95 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SMH trades at $558.83, up 0.54% with a bearish technical signal from moving averages. The ETF faces sector volatility amid AI-driven selloffs, with key support at $547 and resistance at $566. Recent news highlights institutional accumulation by Assetmark Inc. while chip stocks correct from highs.
Outlook hinges on semiconductor cycle resilience; risks include crowded trades and geopolitical tensions. Diversification within SMH’s top-heavy portfolio may cushion volatility, but investor caution is warranted given bearish momentum and sector reset warnings from BofA (Market Watch, July 17, 2026).
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →